ChemicalBook > CAS DataBase List > EFIPLADIB
EFIPLADIB
- Product Name
- EFIPLADIB
- CAS No.
- 381683-94-9
- Chemical Name
- EFIPLADIB
- Synonyms
- PLA902;PLA 902;PLA-902;EFIPLADIB;Efipladib (PLA 902);4-(3-(1-benzhydryl-5-chloro-2-(2-((3,4-dichlorophenyl)MethylsulfonaMido)ethyl)-1H-indol-3-yl)propyl)benzoic acid;4-(3-(5-chloro-2-(2-(((3,4-dichlorobenzyl)sulfonyl)aMino)ethyl)-1-(diphenylMethyl)-1H-indol-3-yl)propyl)benzoic acid;Benzoic acid, 4-[3-[5-chloro-2-[2-[[[(3,4-dichlorophenyl)methyl]sulfonyl]amino]ethyl]-1-(diphenylmethyl)-1H-indol-3-yl]propyl]-
- CBNumber
- CB81011218
- Molecular Formula
- C40H35Cl3N2O4S
- Formula Weight
- 746.14
- MOL File
- 381683-94-9.mol
More
Less
EFIPLADIB Property
- Boiling point:
- 891.2±75.0 °C(Predicted)
- Density
- 1.32±0.1 g/cm3(Predicted)
- pka
- 4.34±0.10(Predicted)
More
Less
N-Bromosuccinimide Price
American Custom Chemicals Corporation
- Product number
- API0019232
- Product name
- 4-(3-(1-BENZHYDRYL-5-CHLORO-2-(2-((3,4-DICHLOROPHENYL)METHYLSULFONAMIDO)ETHYL)-1H-INDOL-3-YL)PROPYL)BENZOIC ACID
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $499.62
- Updated
- 2021/12/16
More
Less
EFIPLADIB Chemical Properties,Usage,Production
Uses
Treatment of pain and symptomatic management of arthritis.
in vivo
Efipladib (100 mg/kg; p.o.; BID for 31 days) reverses the severity in mouse collagen-induced arthritis (CIA) model[1].
Efipladib (100 mg/kg; p.o.; once) significantly inhibits the nociceptive response 1 h after administration in the rat Complete Freund’s Adjuvant (CFA) nociception model[2].
Efipladib is unable to cross the BBB to gain access to the central compartment[2].
Efipladib (100 nM; IT; 5 μL) reduces PGE2 levels in the cerebrospinal fluid in rats[2].
| Animal Model: | Mouse collagen-induced arthritis (CIA) model[1] |
| Dosage: | 100 mg/kg |
| Administration: | PO, BID for 31 days |
| Result: | Gave a dramatic reduction in the clinical disease severity score relative to the vehicle treated group. |
| Animal Model: | Male Sprague-Dawley rats[2] |
| Dosage: | 100 nM in 5 μL of 100% DMSO/rat |
| Administration: | Intrathecal administration |
| Result: | Reduced PGE2 levels in the cerebrospinal fluid (CSF) by 45-60%, yet there was no effect on the nociceptive response. |
IC 50
cPLA2α: 0.04 μM (IC50); cPLA2α: 0.067 μM (Ki)
EFIPLADIB Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
EFIPLADIB Suppliers
- Tel
- sales@ahpharmatech.com
- Country
- China
- ProdList
- 5734
- Advantage
- 55
- Tel
- 025-85560043 15850508050
- Fax
- 025-85563444
- cindy.huang@synzest.com
- Country
- China
- ProdList
- 12000
- Advantage
- 58
- Tel
- 15002134094
- marketing@targetmol.cn
- Country
- China
- ProdList
- 29257
- Advantage
- 58